Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have received an average rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $11.75.

Several research analysts have commented on the stock. Canaccord Genuity Group raised their price target on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. HC Wainwright raised their price target on Regulus Therapeutics from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. SVB Leerink assumed coverage on Regulus Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating and a $6.00 target price for the company. Wells Fargo & Company raised their price objective on Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 13th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Regulus Therapeutics in a research note on Monday, March 18th.

Institutional Investors Weigh In On Regulus Therapeutics

Large investors have recently made changes to their positions in the business. Victory Capital Management Inc. lifted its stake in Regulus Therapeutics by 16.5% in the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 38,529 shares during the period. Opaleye Management Inc. bought a new stake in shares of Regulus Therapeutics during the first quarter valued at approximately $490,000. Vanguard Group Inc. grew its stake in Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares during the period. FMR LLC raised its holdings in Regulus Therapeutics by 32.4% in the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after purchasing an additional 716,000 shares in the last quarter. Finally, CVI Holdings LLC purchased a new position in Regulus Therapeutics during the first quarter valued at $4,050,000. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Price Performance

Shares of RGLS opened at $1.79 on Wednesday. The firm has a market cap of $116.86 million, a PE ratio of -1.22 and a beta of 1.64. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The stock’s fifty day moving average price is $2.24 and its two-hundred day moving average price is $1.92.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.14). Sell-side analysts anticipate that Regulus Therapeutics will post -0.59 earnings per share for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.